Great news for MSB today as well, 100 day survival data in their paediatric phase 3 GVHD trial. Overall survival after 100 days of 75%. Smaller numbers in the CYP studies being phase 1, but definitely promising greater efficacy.... Good luck to MSB with getting their product to market, hopefully CYP won't be too far behind, at a drastically reduced cost.
Great news for MSB today as well, 100 day survival data in their...
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.010(3.85%) |
Mkt cap ! $44.90M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.5¢ | 25.0¢ | $5.869K | 22.42K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29342 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 15.47pm 11/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |